Heart rhythm · 2011
Trends in early and late mortality in patients undergoing coronary catheterization for myocardial infarction: implications on observation periods and risk factors to determine ICD candidacy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bunch T Jared, May Heidi T, Bair Tami L, Crandall Brian G, Weiss J Peter, Osborn Jeffrey S, Anderson Jeffrey L, Muhlestein Joseph B, Horne Benjamin D, Lappe Donald L, Day John D
Аннотация
BACKGROUND: Survivors of acute myocardial infarction (MI) are at high risk for death from both sudden cardiac death and progressive heart failure.
OBJECTIVE: This study sought to determine mortality trends, identify markers of risk, and determine whether outcomes in high-risk patients are altered by revascularization during the implantable cardioverter-defibrillator candidacy observation period.
METHODS: We included 16,793 patients that presented to the catheterization laboratory for acute management of an MI. All patients had 3 years of follow-up to define short- and long-term mortality.
RESULTS: Across the demographics studied there were no significant differences in baseline characteristics over time, with exception of an observed decline in patients with an ejection fraction (EF) ≤0.35. Nonetheless, at study closure 16.3% of all cases had an EF ≤ 0.35. There was a gradual increase in use of percutaneous coronary intervention and coronary artery bypass graft; however, at the end of the study, the highest level of revascularization use was slightly >50%. For the composite, right and left bundle branch block or QRS > 120, the death rates at 1 and 5 years were 31.8% and 46.8%, respectively. These 1- and 5-year mortality rates were increased with an EF ≤ 0.35 (36.0%, 60.2%). Mortality in those with EF ≤ 0.35 exceeded 20% in all groups with conduction system disease at 90 days and was not significantly impacted by percutaneous coronary intervention.
CONCLUSION: The highest risk for death after MI is in patients with an EF ≤ 0.35 and/or conduction system disease. The mortality risk is most pronounced in the early observation period after MI when patients must wait to be considered for an implantable cardioverter-defibrillator.
OBJECTIVE: This study sought to determine mortality trends, identify markers of risk, and determine whether outcomes in high-risk patients are altered by revascularization during the implantable cardioverter-defibrillator candidacy observation period.
METHODS: We included 16,793 patients that presented to the catheterization laboratory for acute management of an MI. All patients had 3 years of follow-up to define short- and long-term mortality.
RESULTS: Across the demographics studied there were no significant differences in baseline characteristics over time, with exception of an observed decline in patients with an ejection fraction (EF) ≤0.35. Nonetheless, at study closure 16.3% of all cases had an EF ≤ 0.35. There was a gradual increase in use of percutaneous coronary intervention and coronary artery bypass graft; however, at the end of the study, the highest level of revascularization use was slightly >50%. For the composite, right and left bundle branch block or QRS > 120, the death rates at 1 and 5 years were 31.8% and 46.8%, respectively. These 1- and 5-year mortality rates were increased with an EF ≤ 0.35 (36.0%, 60.2%). Mortality in those with EF ≤ 0.35 exceeded 20% in all groups with conduction system disease at 90 days and was not significantly impacted by percutaneous coronary intervention.
CONCLUSION: The highest risk for death after MI is in patients with an EF ≤ 0.35 and/or conduction system disease. The mortality risk is most pronounced in the early observation period after MI when patients must wait to be considered for an implantable cardioverter-defibrillator.